On Jan 03, Nanavaty Maulik, SVP & Pres, Neuromodulation sold 5,025 shares of Boston Scientific Corporation (NYSE: BSX), with the average selling price of the stock being $44.73 per share. The total amount realized from this sold $224,757. A document was filed with the Securities and Exchange Commission to notify the public about the sold of the shares.
In addition to that, EVP & Pres, Interven Cardio – Ballinger Kevin J. sold an extra 11,036 shares of this stock in a transaction that took place a day before, on Jan 03, with a share sold at an average of $44.52 and a total of $491,323 was realized from this transaction. After the transaction, the EVP & Pres, Interven Cardio – Ballinger Kevin J. was left with 80,057 shares of the company’s stock, which is currently worth around $3564137.64.
The recent price movement of BSX means that it is now down by -8.69% from its 52-week high and 23.95% up against its 52-week low prices. Over the past one week, the price volatility of BSX stands at 1.48% while the volatility over the past one month is 1.42%. The beta score for this stock is 0.86. A beta score below 1 means that the stock has a low volatility while above 1 signifies that a stock is highly volatile at that particular moment, a data that traders use to keep tabs on their investments.
The company on 10/23/2019 published its latest quarterly earnings, with the report showing that the company recorded 0.39 earnings per share (EPS) during that period. This report was above the expectations of analysts of 0.37 by 0.02. The revenue by the firm was 2.93B for the quarter.
The shares of Boston Scientific Corporation (BSX) dropped by -0.21%, leading to a loss of -$0.09 per share, and saw BSX end the trading session at $42.57 on Wednesday 01/15/20. BSX started the trading session at $42.81, before reaching a daily high of $42.83. It wasn’t able to sustain that growth though and soon jumped to hit a daily low of $42.34.
The trading volume on Wednesday stood at 12718818, which was below the stock’s 3-month average volume of 6.75 million shares, out of a total 1.39B shares. As the price of the stock dipped, the market valuation of the company dropped to 59.39 billion.
The shares of B&G Foods Inc. (NYSE: BGS) went down by -3.60% by the end of the recent trading session. This movement saw its price plunge to close at $15.80, which was lower than the previous closing price of $16.39. Over the past one week, the price of BGS has slipped by -4.30%, while it has recorded a loss of -5.39% over the past one month. Its three-month performance saw BGS lose -4.59% while its six-month performance saw it drop by -21.98%. The situation is different though over the past one year, as the stock price went down by -47.87%, while its year-to-date (YTD) price performance slipped by -11.88%. The stock price has gone up by +11.27% compared to its 90-day low, while it is down -13.59% compared to its 90-day high price.
Let’s take a look at its short, medium and long-term indicators. Composite Indicators shows that Trendspotter rated the stock as a Sell. In the short-term, the stock has a 20-day average volume of 1,352,230 shares, with the short-term indicators averagely rating the stock as a 50% Sell. A look at its medium-term indicators reveals that it has a 50-Day average volume of 1,208,990 shares and the indicators have an average rating of 100% Sell. The last indicators, the long-term see BGS stock with a 100-Day average volume of 1,296,540 shares, giving it an average rating of 100% Sell. A look at the general picture of all short, medium and long-term indicators leaves BGS with an average rating of 88% Sell.
Several brokerage firms sent out their reports BGS stock not long ago. In its report sent out on June 12, 2019, Evercore ISI lowered its ratings on BGS to a In-line. In an earlier report on February 27, 2019, Buckingham Research Downgrade the stock from a Buy to a Neutral. CL King meanwhile in its report on December 12, 2018 Initiated its rating of the stock to “Buy”.
In related news to the company’s stock, around 93.90% shares are being held by institutional investors. In a recent SEC filing, the company revealed that 331 institutions currently hold the BGS stock. In the last quarter, a 59,575,537 BGS shares were in the possession of institutions. On the other hand, the company recorded 33 new institutions who bought it their stock, while 62 institutions sold their entire BGS reserve. Of the current institutions investing in the stock, 130 increased their investment while 154 decreased their investment in the stock.